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Background: Pulmonary exacerbation is one of the main risk factors for death in patients with cystic fibrosis.
Several biomarkers have proven useful in the diagnosis and treatment of pulmonary exacerbations, although none
has been associated with severity. The objective of the present study was to investigate whether C-reactive protein
(CRP) level was associated with the severity of pulmonary exacerbation requiring admission to hospital in patients
with cystic fibrosis.
Methods: We designed a severity index for exacerbations based on 4 clinical parameters and determined whether
there was an association between CRP levels and severity of the exacerbation. We also investigated the association
between CRP and baseline functional and clinical variables.
Results: Twenty-seven patients with cystic fibrosis required 62 admissions to hospital. CRP levels were not
significantly associated with the severity index, although they were associated with specific patient characteristics:
colonization by Pseudomonas aeruginosa, allergic bronchopulmonary aspergillosis, treatment with oral corticosteroids,
and number of severe exacerbations treated with intravenous antibiotics during the previous year.
Conclusions: CRP level is not associated with the severity of pulmonary exacerbations, but it is associated with specific
clinical characteristics. This simple scoring system (severity index) could prove very useful for evaluating the severity of
exacerbations.
Keywords: CRP, Cystic fibrosis, Respiratory exacerbation, Hospital admission, Pseudomonas aeruginosa, Corticosteroids,
Allergic bronchopulmonary aspergillosis, Severity indexBackground
Cystic fibrosis (CF) is the most common fatal autosomal
recessive disease in Caucasian individuals. It affects ap-
proximately 1 in every 4500 live-born infants, follows a
chronic course, and involves several body systems. The
main cause of morbidity and mortality continues to be pro-
gressive respiratory impairment, which is responsible for
95% of deaths [1]. Respiratory impairment arises from the
inability of the mucociliary system to eliminate thick, dehy-
drated secretions, thus generating bronchial obstruction,* Correspondence: rmgiron@gmail.com
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article, unless otherwise stated.inflammation, and recurrent infections that damage the
bronchial wall and give rise to bronchiectasis. Patients af-
fected by this chronic disease often present with acute su-
perinfections or exacerbations caused by the emergence of
new pathogens, an increase in habitual bacterial load, or
the host inflammatory response, each of which leads to im-
paired respiratory function and a poor prognosis [2-4].
No consensus has been reached on the definition of a
pulmonary exacerbation or on diagnostic variables [5-14].
In the absence of objective markers, most published trials
define a moderate-severe exacerbation as one requiring
admission to hospital or intravenous antibiotics. No validated
scoring systems have been designed for early detection of a
pulmonary exacerbation, although the clinical picture, which
is accompanied by a decrease in lung function parameters,Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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eters in a specialized unit and follow-up are key elements
for early diagnosis and initiation of suitable immediate
therapy [15].
A recent exhaustive review of the usefulness of blood bio-
markers of pulmonary exacerbations in patients with cystic
fibrosis shows that C-reactive protein (CRP) is the most
widely studied marker and that others (neutrophil elastase,
antiproteinase complex, interleukin 6, myeloperoxidase,
lactoferrin, and calprotectin) seem promising [16].
CRP has high diagnostic sensitivity for inflammatory
processes, although its specificity is low. It can prove
useful when selecting candidates for treatment or inves-
tigating whether or not treatment is efficacious once
started. The availability of quantitative methods is im-
portant when determining CRP levels.
Several studies have analyzed the value of CRP in the
diagnosis of pulmonary exacerbation in patients with
cystic fibrosis and in monitoring the response of the ex-
acerbation to treatment [17-31]. The results show that
CRP increases during exacerbations and decreases with
treatment. However, data on whether CRP can predict
or is correlated with severity of pulmonary exacerbations
are lacking. Therefore, the primary objective of the
present study was to verify whether elevated CRP values
at the onset of a pulmonary exacerbation are associated
with greater severity of the exacerbation. The secondary
objective was to ascertain whether baseline characteris-
tics are associated with CRP values.
Methods
Our study population comprised all consecutive patients
diagnosed with cystic fibrosis who were admitted to La
Princesa University Hospital, Madrid, Spain with a moder-
ate to severe pulmonary exacerbation. The study period
lasted 3 years (January 1, 2009 until December 31, 2011).
This research was approved by the La Princesa Ethics
Committee (Madrid, Spain). The patients who signed an
informed consent prior to being involved in the study
were enrolled. In the case of one of the patients involved
who was under eighteen years old this informed consent
was signed by one of their parents.
Based on the criteria of Fuchs et al. [5], patients were con-
sidered to have had a pulmonary exacerbation if they had at
least 4 of the following symptoms or signs: increased cough
and expectoration, purulent sputum, hemoptysis, loss of
appetite and weight, dyspnea, fever, decrease of >10% in
forced expiratory volume in 1 second (FEV1) and/or oxy-
gen saturation with respect to baseline values, changes in
lung sounds, and radiographic evidence of new infiltrates.
Transplant recipients and patients with associated
diseases that could increase CRP levels were excluded
(e.g., vasculitis, arthritis, connective tissue disorders, pan-
creatitis, neoplasm, or heart problems).We recorded the following clinical variables: sex, age at
the first episode, presence of pancreatic insufficiency (de-
fined as fecal elastase levels <200 μg/g and need for pan-
creatic enzymes), genetic mutations, CF-related diabetes
(defined as the need for insulin treatment to control blood
sugar levels), allergic bronchopulmonary aspergillosis
(if the consensus diagnostic criteria were met [32]), bacter-
ial colonization (isolation of the same germ in 3 consecu-
tive sputum samples separated by an interval of 1 month),
continuous treatment received during the 3 months be-
fore the episode (macrolides, inhaled corticosteroids, oral
corticosteroids, ibuprofen, nebulized antibiotics, DNase,
or hypertonic saline solution), and the number of exacer-
bations during the previous year (specifying whether anti-
biotic therapy was oral or intravenous).
Lung function values were collected at baseline and at the
end of intravenous antibiotic therapy. Baseline lung function
was defined as the best value from the previous year. All pa-
tients underwent spirometry at the clinic (Datospir 120,
Síbel); FEV1 and forced vital capacity (FVC) were expressed
as absolute values (liters) and as a percentage of the pre-
dicted value. The FEV1/FVC ratio was calculated.
A chest radiograph was taken at admission and compared
with the previous radiograph to detect new pathologic find-
ings. We also recorded the intravenous antibiotics taken to
treat the exacerbation and the number of days on intraven-
ous therapy, specifying the number of days with treatment
at hospital and at home (hospitalized patients whose symp-
toms improved were discharged and continued treatment
at home). Complications during the exacerbation were re-
corded (i.e., hemoptysis, pneumothorax, respiratory insuffi-
ciency, need for noninvasive mechanical ventilation, need
for invasive mechanical ventilation, and death).
A blood sample was taken during the first 48 hours to
obtain the following parameters: total leukocytes, erythro-
cyte sedimentation rate (ESR), immunoglobulins (IgG,
IgM, and IgA), fibrinogen, and CRP. This last one was
measured by immunoturbidimetric assay (Tina-quant
CRP detection method; Roche Diagnostics) at our hospital
clinical laboratory.
Pulmonary exacerbation severity index
An index was constructed to determine the severity of pul-
monary exacerbations. The index was based on 4 parameters:
a. Loss of lung function after an exacerbation:
(baseline FEV1 – initial FEV1)/baseline FEV1, scored as
follows: <15% = 0; ≥15% = 1
b. Recovery of lung function after an exacerbation:
Final FEV1/baseline FEV1, scored as follows: ≥90% = 0, <
90% = 1
Table 1 Clinical characteristics of the patients (n = 27)
Clinical variable Value
Age, y mean (SD) 25.9 (6.7)
Sex, man/woman (n) 10/17
Lung function tests: mean (SD)
FVC, L 3.0 (0.84)
FVC, % predicted 73.8 (18.8)
FEV1, L 1.9 (0.6)
FEV1, % predicted 53.2 (16.3)
FEV1/FVC 61.1 (11.3)




Diabetes, n (%) 5 (18.5)
ABPA, n (%) 11 (40.7)
Pancreatic insufficiency, n (%) 24 (88.9)
Bacterial colonization, n (%)
Staphylococcus aureus 18 (66.7)
MRSA 4 (14.8)
Pseudomonas aeruginosa 23 (85.2)
Burkholderia cepacia 3 (7.4)
Achromobacter xylosoxidans 6 (21.7)
Haemophilus influenzae 1 (3.7)
Stenotrophomonas maltophilia 1 (3.7)
Treatment, n (%)
Macrolides 22 (81.5)
Inhaled corticosteroids 21 (77.8)
Oral corticosteroids 5 (18.5)
Nebulized antibiotics 23 (85.2)
DNase 14 (51.9)
Hypertonic saline solution 13 (48.1)
No. of exacerbations during the previous
year treated with oral antibiotics, mean (SD)
3.2 (1.9)
No. of exacerbations during the previous year
treated with intravenous antibiotics, mean (SD)
1.77 (1.73)
FVC, forced vital capacity; FEV1, forced expiratory volume in the first second;
ABPA, allergic bronchopulmonary aspergillosis; MRSA, methicillin-resistant
Staphylococcus aureus.
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hospital
≤ 14 days = 0, > 14 days = 1
d. Complications:
No = 0, Yes = 1
Baseline FEV1 corresponded to the value of FEV1 dur-
ing the stable phase (the best value during the previous
year), initial FEV1 to the FEV1 value at the initiation of
antibiotic therapy administered to treat the exacerbation,
and final FEV1 to the FEV1 value at the end of antibiotic
therapy. Number of days receiving IV antibiotics in hos-
pital was chosen as one of the items instead of total
number of days of IV antibiotics (including antibiotics at
home) because the first one reflects more appropriately
the severity of an exacerbation: many times in clinical
practice, patients are discharged from hospital but they
keep routinely taking medicines for some days in spite
of the fact that their exacerbation is considered resolved.
The values of the index ranged from 0 to 4. Patients
with values of 3 and 4 were grouped together owing to
the small number of patients in each of the original
groups; therefore, the possible values for the index were
0, 1, 2, and 3.
Statistical analysis
The results were analyzed using SPSS version 19 (SPSS
Inc). Normality was verified using the Kolmogorov-
Smirnov test; in the case of a non-normal distribution,
nonparametric tests were used (Spearman correlation,
Mann–Whitney, and Kruskal-Wallis). In the descriptive
analysis, the quantitative variables were expressed as
mean (SD) and the qualitative variables as percentages.
When a patient suffered multiple pulmonary exacerba-
tions along the study period, each exacerbation was ana-
lyzed as a separate event. The percentage of loss and
recovery of FEV1 was calculated using the formulas de-
scribed above. Initial CRP values were associated with
the severity index and with the following baseline clin-
ical variables: sex, age, genotype, bacterial colonization,
pancreatic insufficiency, diabetes, allergic bronchopul-
monary aspergillosis, previous treatment, number of ex-
acerbations, and baseline FEV1. A sensitivity analysis of
the association between CRP and the severity index was
performed selecting the exacerbations with CRP mea-
surements within 24 hours after hospital admission.
Multivariable analysis using linear regression (stepwise
variable selection method) was conducted with baseline
clinical variables showing statistically significant associ-
ation with CRP.
Statistical significance was set at p < 0.05.Results
The study population comprised 27 patients with cystic fi-
brosis aged 15 to 45 years, each of whom had experienced
at least 1 pulmonary exacerbation during the study period.
The colonizing microorganism was Pseudomonas aerugi-
nosa in 85.2% of cases; mean baseline FEV1 (% predicted)
was 53.2% (Table 1).
During the study period, the 27 patients experienced
62 exacerbations requiring admission to hospital and
intravenous antibiotic treatment (tobramycin in 61% of
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nem in 30%). Prior to admission, 25 (40.3%) exacerbations
were treated with oral antibiotics (19.4% with quinolones,
9.7% with amoxicilin, 8.1% with co-trimoxazole and 3.2%
with others) for 3 to 7 days in 9 (14.5%) cases, 8 to14 days
in 11 (17.7%), and 21 days in 5 (8.1%). On average, the fall
in FEV1 after the exacerbation was approximately 10%
and the subsequent recovery only 7% (Figure 1). Some
markers of inflammation were increased (CRP, ESR, and
fibrinogen). Patients were hospitalized for a mean of 10.4
days and received intravenous antibiotic therapy for 17
days (Table 2).
CRP was measured within the first 24 hours after hos-
pital admission in half of the exacerbation episodes; in
the other half CRP was obtained at 48 hours. The correl-
ation between CRP and the severity index was not statisti-
cally significant in either the whole sample (Spearman’s
rho, 0.203; p = 0.134) or the subgroup with CRP measure-
ments within 24 hours (Spearman’s rho, 0.193; p = 0.344)
(Figure 2). No correlation between the severity index and
other inflammatory markers (leukocytes, ESR, IgG, IgA,
IgM and fibrinogen) was found (data not shown).Figure 1 FEV1 (% predicted) before and after exacerbations. The boxe
patients in each group. The horizontal line within the box represents the m
before admission (baseline); FEV1 at hospitalization (initial); and the best FEMean values of CRP were similar in patients previously
treated or not treated with oral antibiotics (4.2 vs 3.8; p =
0.405). Duration of previous treatment with oral antibiotics
didn’t seem to influence the CRP values either: 4.8 mg/dL,
3.6 mg/dL, and 4.4 mg/dL in patients treated for 3 to7
days, 8 to 14 days, and 21 days, respectively (p = 0.823).
Analysis of the association between CRP and baseline
characteristics revealed higher CRP levels in patients colo-
nized by P. aeruginosa (4.4 vs 2.2; p = 0.016), patients diag-
nosed with allergic bronchopulmonary aspergillosis (4.9 vs
2.9; p = 0.024), patients taking oral corticosteroids (6.1 vs 3.0;
p = 0.010), and patients who had had a larger number of ex-
acerbations treated with intravenous antibiotics during the
previous year (p = 0.001). Association between CRP and the
rest of baseline characteristics was not statistically significant.
After the multivariable analysis, only treatment with oral cor-
ticosteroids was identified as independent factor associ-
ated with CRP values (beta coefficient = 3.013; p = 0.005).
Discussion
Pulmonary exacerbations in patients with cystic fibrosis
can lead to a gradual decline in lung function, impaireds represent the middle 50% of patients; the whiskers include all
edian FEV1. The x axis represents the best FEV1 in the 12 months
V1 at the end of antibiotic therapy (final).
Table 2 Characteristics of the exacerbations (n = 62)
Variable Value
Lung function tests, mean (SD)
Initial FEV1, L 1.50 (0.5)
Initial FEV1, % predicted 43.9 (15.6)
Final FEV1, L 1.7 (0.5)
Final FEV1, % predicted 50.3 (17.3)
C-reactive protein, mg/dL, mean (SD)
Severity index, 0 (n = 10) 2.4 (3.2)
Severity index, 1 (n = 22) 4.5 (4.0)
Severity index, 2 (n = 17) 3.0 (2.4)
Severity index, 3 (n = 7) 5.9 (4.8)
Other markers of inflammation, mean (SD)
Leukocytes, cells/mL 10,532 (4,738)
ESR, mm/h 45.8 (24.2)
Total non-specific IgG, mg/dL 1371.8 (408.7)
Total non-specific IgA, mg/dL 298.6 (94.1)
Total non-specific IgM, mg/dL 155.9 (80.9)
Fibrinogen, mg/dL 547.1 (135.3)
Hospital stay, days, mean (SD) 10.4 (6.5)
Home intravenous treatment, days, mean (SD) 6.7 (4.9)
Chest radiograph, n (%)
Not done 1 (1.6)
Worse 25 (40.3)
Similar to previous 36 (58.1)
Main complications during exacerbations, n (%)
Hemoptysis 13 (21)
Pneumothorax 2 (3.2)
Respiratory insufficiency 24 (38.7)
Noninvasive mechanical ventilation 1 (1.6)
Invasive mechanical ventilation 1 (1.6)
FEV1, forced expiratory volume in the first second; ESR, erythrocyte
sedimentation rate; Ig, immunoglobulin.
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they have a negative impact on prognosis, since survival
decreases [1-4]. In the present study, we investigated the
potential association between CRP level and the severity of
pulmonary exacerbations requiring hospital admission in
patients with cystic fibrosis and ascertained whether CRP
level was associated with specific clinical characteristics.
In the absence of validated scoring systems, we attempted
to meet our first objective by determining the severity of
exacerbations through the design of a simple, user-friendly
score based on 4 parameters considered important when
evaluating the severity of an exacerbation in clinical prac-
tice. We used these parameters to construct a severity
index with values ranging from 0 to 4, in which the least se-
vere exacerbation was scored 0 and the most severe 4. Incontrast with the proposed hypothesis, CRP levels were not
significantly associated with the severity index.
A recent and exhaustive systematic review of all stud-
ies in which blood biomarkers of respiratory exacerba-
tions in CF patients were analyzed concluded that CRP
was the most widely studied marker [16]. CRP levels
usually increase significantly at the onset of an exacerba-
tion [17-21], although this parameter does not enable us
to identify the causative microorganism [19,20,22,23].
The role of CRP in predicting the duration, frequency,
and recurrence rate of pulmonary exacerbations has also
been evaluated [24-26], and an inverse association be-
tween CRP and time until the subsequent exacerbation
has been reported [26]. The most widely studied aspect
of CRP is its role in the response to treatment of an
exacerbation. Many studies show a significant decrease
in CRP after antibiotic treatment [17,19,20,22-25,27-31].
However, to date, the usefulness of biomarkers for deter-
mining the severity of a pulmonary exacerbation has not
been evaluated [16], thus giving more weight to the hy-
pothesis proposed in the present study, namely, that the
increase in CRP is greater in more severe exacerbations.
The fact that we did not find a significant association
between CRP values and the severity of an exacerbation
leads us to think that this biomarker may not be useful
for measuring the severity of pulmonary exacerbations
in patients with cystic fibrosis or that it is only useful in
specific subgroups. For example, Ibrahim et al. [33] ana-
lyzed 628 episodes of exacerbation and found that a sub-
group of patients with higher FEV1 values, less impaired
lung function, and no colonization by P. aeruginosa had
normal CRP levels and needed fewer days of treatment.
The authors concluded that very aggressive regimens
should not be used in this subgroup. As the plasma half-
life of CRP is about 19 hours [34], CRP levels might fall
quickly in patients responding to treatment and the CRP
value might have less ability to predict exacerbation se-
verity if the measurement was delayed. However, the
analysis in the subgroup of exacerbations which CRP
values were early obtained (first 24 hours) did not show
relationship between CRP and the severity index.
When we analyzed the association between CRP and
baseline characteristics, we found a significant association
with colonization by P. aeruginosa, diagnosis of allergic
bronchopulmonary aspergillosis, current treatment with oral
corticosteroids, and the number of exacerbations requiring
intravenous antibiotic treatment during the previous year.
Our results show that patients colonized by P. aerugi-
nosa have higher CRP levels, as reported by Watkin et al.
[22], who concluded that patients intermittently colonized
by other bacteria, such as Haemophilus influenzae or
Staphylococcus aureus, had lower CRP levels. A recent
publication on inflammation and microbiota in pulmonary
exacerbations in patients with cystic fibrosis found that
Figure 2 Correlation between C-reactive protein and pulmonary exacerbation severity index. A. Correlation between CRP and severity
index for all the exacerbations. B. Correlation between CRP and severity index for exacerbations with CRP measurement within 24 hours after
hospital admission. The circles represent the values of CRP at the beginning of each exacerbation. The x axis represents the group of
exacerbations according its severity index. The horizontal line within the group represents the median CRP value.
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onies had lower FEV1 values and higher CRP values, in
contrast with the remaining bacteria studied [35].
In cystic fibrosis, recurrent infection and obstruction
of the airways lead to inflammation, lung damage in the
long term, respiratory insufficiency, and death [36].Given that inflammation is present from onset, anti-
inflammatory drugs such as corticosteroids could prove
useful for delaying impairment of lung function in the
long term. However, owing to the severe side effects of
these drugs, long-term use is not recommended, except
in very specific cases. Paradoxically, in our study, patients
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anti-inflammatory effect, had higher CRP levels than
patients who did not. In fact, this variable was the
only one that remained significant after conducting a
multivariable analysis. This observation could be explained
by the fact that corticosteroid therapy is likely initiated in
patients with greater respiratory impairment and in-
creased levels of inflammatory markers.
Our study is subject to a series of limitations. First, the
sample size is small owing to the low prevalence of
cystic fibrosis and to the fact that it was performed in a
single hospital. In order to definitively rule out the hy-
pothesis established, we should perform a multicenter
study with a higher number of patients and pulmonary
exacerbations. Second, we did not analyze more com-
plex inflammatory markers or perform serial determi-
nations of CRP, both of which would have generated more
robust conclusions. For example, neutrophil elastase and
interleukin-8 are important biomarkers in detecting and
monitoring pulmonary exacerbations [16,37,38] so they
may be more relevant to the severity index than CRP.
Finally, we used a non-validated scoring system (severity
index) and therefore it might not be comprehensive
enough to evaluate the severity of the exacerbations;
nevertheless, we consider the score to be very useful, since
it enabled us to classify the intensity of the exacerbations.
Conclusion
Our findings enable us to conclude that CRP levels are
not associated with the pulmonary exacerbation severity
index but that they are associated with some clinical var-
iables, such as colonization by P. aeruginosa, number of
exacerbations treated with intravenous antibiotics during
the previous year, treatment with oral corticosteroids,
and allergic bronchopulmonary aspergillosis. A simple
scoring system, such as the severity index, could prove
useful for classifying the severity of pulmonary exacerba-
tions in patients who require intravenous treatment and
would enable us to act accordingly.
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